CSBR
Price
$7.76
Change
+$0.54 (+7.48%)
Updated
Jun 27 closing price
Capitalization
107.3M
17 days until earnings call
PHAT
Price
$9.74
Change
+$0.19 (+1.99%)
Updated
Jun 27 closing price
Capitalization
679.99M
38 days until earnings call
Interact to see
Advertisement

CSBR vs PHAT

Header iconCSBR vs PHAT Comparison
Open Charts CSBR vs PHATBanner chart's image
Champions Oncology
Price$7.76
Change+$0.54 (+7.48%)
Volume$40.47K
Capitalization107.3M
Phathom Pharmaceuticals
Price$9.74
Change+$0.19 (+1.99%)
Volume$1.24M
Capitalization679.99M
CSBR vs PHAT Comparison Chart in %
Loading...
CSBR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PHAT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CSBR vs. PHAT commentary
Jun 30, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CSBR is a Buy and PHAT is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 30, 2025
Stock price -- (CSBR: $7.76 vs. PHAT: $9.74)
Brand notoriety: CSBR and PHAT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CSBR: 115% vs. PHAT: 38%
Market capitalization -- CSBR: $107.3M vs. PHAT: $679.99M
CSBR [@Biotechnology] is valued at $107.3M. PHAT’s [@Biotechnology] market capitalization is $679.99M. The market cap for tickers in the [@Biotechnology] industry ranges from $304.6B to $0. The average market capitalization across the [@Biotechnology] industry is $2.32B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CSBR’s FA Score shows that 1 FA rating(s) are green whilePHAT’s FA Score has 0 green FA rating(s).

  • CSBR’s FA Score: 1 green, 4 red.
  • PHAT’s FA Score: 0 green, 5 red.
According to our system of comparison, CSBR is a better buy in the long-term than PHAT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CSBR’s TA Score shows that 4 TA indicator(s) are bullish while PHAT’s TA Score has 4 bullish TA indicator(s).

  • CSBR’s TA Score: 4 bullish, 6 bearish.
  • PHAT’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, PHAT is a better buy in the short-term than CSBR.

Price Growth

CSBR (@Biotechnology) experienced а -7.62% price change this week, while PHAT (@Biotechnology) price change was -6.53% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.13%. For the same industry, the average monthly price growth was +31.22%, and the average quarterly price growth was +12.91%.

Reported Earning Dates

CSBR is expected to report earnings on Jul 17, 2025.

PHAT is expected to report earnings on Aug 07, 2025.

Industries' Descriptions

@Biotechnology (+4.13% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PHAT($680M) has a higher market cap than CSBR($107M). PHAT YTD gains are higher at: 19.951 vs. CSBR (-9.452). CSBR has higher annual earnings (EBITDA): 8.43M vs. PHAT (-272.12M). PHAT has more cash in the bank: 212M vs. CSBR (3.2M). CSBR has less debt than PHAT: CSBR (6.44M) vs PHAT (204M). PHAT has higher revenues than CSBR: PHAT (81.9M) vs CSBR (58.6M).
CSBRPHATCSBR / PHAT
Capitalization107M680M16%
EBITDA8.43M-272.12M-3%
Gain YTD-9.45219.951-47%
P/E Ratio16.93N/A-
Revenue58.6M81.9M72%
Total Cash3.2M212M2%
Total Debt6.44M204M3%
FUNDAMENTALS RATINGS
CSBR: Fundamental Ratings
CSBR
OUTLOOK RATING
1..100
50
VALUATION
overvalued / fair valued / undervalued
1..100
83
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
10
PRICE GROWTH RATING
1..100
43
P/E GROWTH RATING
1..100
77
SEASONALITY SCORE
1..100
75

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
CSBRPHAT
RSI
ODDS (%)
Bearish Trend 4 days ago
75%
Bearish Trend 4 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 4 days ago
76%
Bearish Trend 4 days ago
90%
Momentum
ODDS (%)
Bullish Trend 4 days ago
80%
Bearish Trend 4 days ago
82%
MACD
ODDS (%)
N/A
Bearish Trend 4 days ago
85%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
81%
Bearish Trend 4 days ago
86%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
74%
Bullish Trend 4 days ago
83%
Advances
ODDS (%)
Bullish Trend 13 days ago
72%
Bullish Trend 18 days ago
84%
Declines
ODDS (%)
Bearish Trend 5 days ago
79%
N/A
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
90%
Aroon
ODDS (%)
Bearish Trend 4 days ago
76%
Bullish Trend 4 days ago
79%
View a ticker or compare two or three
Interact to see
Advertisement
CSBR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PHAT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RYEUX116.601.37
+1.19%
Rydex Europe 1.25x Strategy H
AILLX27.250.13
+0.48%
Aristotle Core Equity I-2
NSBCX63.510.28
+0.44%
Nuveen Dividend Growth C
HMCRX14.660.04
+0.27%
Harbor Mid Cap Retirement
SAMVX11.590.03
+0.26%
Virtus Ceredex Mid-Cap Value Equity A

CSBR and

Correlation & Price change

A.I.dvisor tells us that CSBR and CVAC have been poorly correlated (+26% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CSBR and CVAC's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CSBR
1D Price
Change %
CSBR100%
+7.48%
CVAC - CSBR
26%
Poorly correlated
N/A
LIXT - CSBR
25%
Poorly correlated
-7.19%
INZY - CSBR
23%
Poorly correlated
-0.25%
PMN - CSBR
23%
Poorly correlated
-0.97%
PHAT - CSBR
23%
Poorly correlated
+1.99%
More

PHAT and

Correlation & Price change

A.I.dvisor indicates that over the last year, PHAT has been loosely correlated with RGNX. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if PHAT jumps, then RGNX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PHAT
1D Price
Change %
PHAT100%
+1.99%
RGNX - PHAT
36%
Loosely correlated
-4.11%
URGN - PHAT
35%
Loosely correlated
+2.90%
ACIU - PHAT
35%
Loosely correlated
-2.90%
CCCC - PHAT
34%
Loosely correlated
-7.89%
PDSB - PHAT
33%
Loosely correlated
-2.76%
More